Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $357.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Canaccord Genuity Group from $283.00 to $357.00 in a research report released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Evercore ISI lifted their […]
More Stories
Homebuilder Confidence Drops in October Amid Weak Demand, Rising Costs
By Bill Pan Confidence among U.S. homebuilders fell in October, as rising mortgage rates discouraged buyers while construction costs and...
Elon Musk Pledges to Give ‘Every Kid in America’ 1 SpaceX Share
By Andrew Moran Billionaire Elon Musk said he will give every child in the United States a stake in his...
Vance Says He’ll Wait Until After Midterms to Decide on Presidential Run
By Jack Phillips Vice President JD Vance said he will wait until after the upcoming November midterm elections before making...
Oil Retreats From 5-Month High as Markets Weigh Trump’s Russia Sanctions Waiver
By Tom Ozimek Oil prices fell on Oct. 19, with Brent retreating from a five-month high as investors weighed President...
The Babysitter 3: Renewal Status, Release Date, Cast Members & Plot
Nine years after Netflix’s debut, the horror-comedy film The Babysitter remains one of the biggest hits. What began as a...
Original Games and Familiar Brands: Two Creative Routes in Online Casino Entertainment
A familiar film title can make a game recognisable before anyone opens it. An original character has a different task,...